

Beovu[®] (brolucizumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of neovascular (wet) age-related macular degeneration

December 17, 2021 · 7 min read

- Beovu[®] is an anti-VEGF that offers the option for eligible patients to start on a three-month dosing interval immediately after the loading phase with no compromise in efficacy.¹²
- While wet age-related macular degeneration (AMD) represents 10 to 20 per cent of all AMD cases, it is the most severe form of AMD and is responsible for 90 per cent of vision loss associated with this disease.³

DORVAL, QC, Dec. 17, 2021 /CNW/ - Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that ^{Pr}Beovu[®] (brolucizumab injection) is now listed on the Ontario Drug Benefit Formulary and the New Brunswick Drug Plan for the treatment of neovascular (wet) agerelated macular degeneration (AMD) for eligible patients.

UNOVARTIS

Novartis Logo (CNW Group/Novartis Pharmaceuticals Canada Inc.)

"We would like to thank the Governments of Ontario and New Brunswick for their leadership in making Beovu[®] accessible for eligible patients and remain committed to working collaboratively with the remaining provinces to ensure patients across the country can benefit from this therapy. Access to this next generation wet AMD treatment will make a difference to the vision health of Canadians and represents

Find authenticated court docum



- Asia May Get Lift From China Stocks Rally in U.S.: Markets Wrap
- 2. UPDATE 1-Putin told Biden new sanctions could rupture U.S.-Russia ties - Kremlin
- 3. Germany's Scholz wants G7 to be pioneer for climate-friendly growth
- 4. Libor Banks Subject to U.S. Conspiracy Jurisdiction, Court Says
- 5. Biden told Putin U.S. will respond decisively if further invasion of Ukraine -White House

Mylan v. Regeneron, IPR2021-00881 U.S. Pat. 9,254,338, Exhibit 2270 Beovu® (brolucizumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of neovascular (wet) a...

🕈 номе	MAIL	NEWS	FINANCE	SPORTS	ENTERTAINMENT	LIFE	SHOPPING	YAHOO PLUS	MORE	y/finance+ (Try it free
yahoo.	ce	Search	Search for news, symbols or companies						Sign in	C Mail	

Affecting more than 2.5 million Canadians, AMD is a chronic disease of the retina that causes progressive loss of central vision and is the leading cause of vision loss in people over the age of 50.^{4,5,6} There are two types of AMD – dry and wet.⁴ In wet AMD, new blood vessels grow under the macula and leak fluid into the eye causing scarring of the macula.⁷ Left untreated, wet AMD can lead to profound, rapid, and permanent loss of sight.^{4,8,9} Vision loss has a significant impact on people's quality of life and mental health – their autonomy is lost, they can't drive, read or see the faces of their loved ones, often leading them to experience feelings of social isolation and depression.^{9,10}

12/30/21 6:31 PM

Q

f

 \sim

DOCKE

"Given wet AMD can be aggressive in its progression and has no cure, it can have a devastating impact on patients and their vision if patients don't adhere to the regular treatment that is required," said Dr. Peter Kertes, MD, ophthalmologist and retinal specialist, Sunnybrook Hospital, Toronto. "As someone who knows how important extended treatment intervals can be for patients, I welcome the news that Beovu[®] is now publicly funded in these provinces, providing a new treatment option for wet AMD."

Anti-vascular endothelial growth factor (anti-VEGF) therapy is widely regarded as the standard of care for patients with wet AMD.¹¹ Approved by Health Canada in March 2020, Beovu[®] is an anti-VEGF that offers the option for eligible patients to start on a three-month dosing interval immediately after the first three doses (loading phase).^{1,2}

"Regular treatment is key to preserving sight and maintaining the independence of people living with wet AMD," said Doug Earle, president and CEO, Fighting Blindness Canada. "It may be challenging to keep up with frequent appointments, especially for those living in remote or isolated communities, or requiring mobility assistance. These issues have further been exacerbated by COVID-19. The Governments of Ontario and New Brunswick's decision to add Beovu[®] to their provincial formularies offers the opportunity to reduce the burden of frequent injections and will be meaningful to provide treatment options for people living with wet AMD and their loved ones."

About Beovu[®] (brolucizumab injection)

Beovu[®] (brolucizumab injection) is a humanized vascular endothelial growth factor (VEGF) inhibitor that binds to VEGF-A isoforms, thereby preventing binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A binding, Beovu[®] suppresses endothelial cell

COLE HAAN THE WINTER SALE TAKE AN Extra 30% Off SALE STYLES WITH CODE: EXTRA SHOP NOW

12/30/21, 6:31 PM

Q

 \sim

Beovu® (brolucizumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of neovascular (wet) a...

🕈 номе	MAIL	NEWS	FINANCE	SPORTS	ENTERTAINMENT	LIFE	SHOPPING	YAHOO PLUS	MORE	y!finance+	Try it free
yahoo	finan ⁽	ce	Search	Search for news, symbols or companies					Q		Mail
	treat	ment of	neovascu	lar (wet) a	ge-related mac	ular de	generation				

(AMD) based on findings from the pivotal HAWK and HARRIER Phase

- f The full prescribing information for Beovu[®] can be found at:
- www.novartis.ca.

About Novartis in Ophthalmology

At Novartis, our mission is to discover new ways to improve and extend people's lives. In ophthalmology, we develop and deliver lifechanging medicines and therapies for diseases and conditions from front to back of the eye, enabled by data and transformative technologies. Our ophthalmic solutions reach more than 150 million people per year, from premature infants to the elderly.

About Novartis Pharmaceuticals Canada Inc.

Novartis Pharmaceuticals Canada Inc., a leader in the healthcare field, is committed to the discovery, development and marketing of innovative products to improve the well-being of all Canadians. In 2020, the company invested \$45 million in research and development in Canada. Located in Dorval, Quebec, Novartis Pharmaceuticals Canada Inc. employs approximately 1,000 people in Canada and is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. The company prides itself on its commitment to diversity and to nurturing an inclusive and inspiring environment. Novartis is recognized as a Great Place to Work[®], ranked among the Top 50 Best Workplaces[™] in the country and is proudly named on the 2021 Best Workplaces[™] for Women in Canada and Best Workplace[™] for Mental Wellness lists. For further information, please consult www.novartis.ca.

About Novartis

Novartis is reimagining medicine to improve and extend people's lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world's top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.

Beovu is a registered trademark.

DOCKET

RM



Find authenticated court documents without watermarks at docketalarm.com.

12/30/21, 6:31 PM

Beovu® (brolucizumab injection) now publicly reimbursed in Ontario and New Brunswick for the treatment of neovascular (wet) a...


HOME	MAIL	NEWS	FINANCE	SPORTS	ENTERTAINMENT	LIFE	SHOPPING	YAHOO PLUS	MORE	y/finance+	Try it fro
ahoo.	finan	ce	Seard	h for news, s	symbols or compa	nies		C	k	Sign in	🔦 Ma
	Doub	le-Masked T	rials of Broluci	zumab for Ne	ovascular Age-Related	l Macular D	Degeneration.				
	Avail	able at: http	s://www.aaojou	urnal.org/artic	le/S0161-6420(18)330	18-5/fullte	t. Accessed on				
0	Dece	mber 2, 202	1.							* ** *	
φ	³ Inst	titut nationa	l d'excellence e	n santé et en :			نه آب	*			
f		othérapie an able at:	tiangiogénique	e dans le traite	ment de la dégénéres	cence mac	ulaire liée à l'âge.		-	COLE HAAN THE WINTER SALE	
			ss.qc.ca/fileadr	nin/doc/INESS		*	TAKE AN				
W			ember 2, 2021.					<u> </u>			
			Related Macul			xtra 30% O	Π				
_			scape.com/vie	s	ALE STYLES WITH CODE: EXT	RA					
\geq			ess Canada. AN	200	SHOP NOW						
	-	-	tingblindness.c	×							
			cil of the Blind.								
	https	://www.fight	tingblindness.c	a/wp-content/		4		* *			
	Blind	ness-in-Cana	ada-May-2021.	odf. Accessed							
	⁷ Am	erican Acade	emy of Ophtha	Imology. What							
	https	://www.aao.	org/eye-health	/diseases/amd							
	2021.										
	⁸ Figh	nting Blindne	ess Canada. Ag								
	https	://www.fight	tingblindness.c	a/eyehealth/ey							
	Acce	ssed on Dece	ember 2, 2021.								
	⁹ Wy	koff CC <i>et al</i>	Optimizing Ar	-							
	Relat	ed Macular I	Degeneration.								
	https	://pubmed.n	cbi.nlm.nih.go								
	¹⁰ An	nerican Macı	ular Degenerat								
	Avail 2021.		s://www.macul								
	¹¹ CA	DTH Therape	eutic Report. A	nti-Vascular E	of						
	Retin	al Condition	s Recommend								
		:://www.cadt mber 2, 202	h.ca/sites/defa 1.	ult/files/pdf/T							
	SOU	IRCE Nov	artis Phar								
	Cisior	1									


View original content to download multimedia:

http://www.newswire.ca/en/releases/archive/December2021/17/c0757.html



Find authenticated court documents without watermarks at <u>docketalarm.com</u>.







RM

Ad • Chaikin Analytics

Wall Street legend warns "A strange day is coming"

A massive and surprising new transition could soon impact the wealth of thousands, while leaving everyone else worse off than before.

...



Yahoo Finance

DOCKE.

Δ

Why Wall Street set new records on the same day COVID-19 cases did

Another day, another shattered record of COVID-19 infections in the United States — and yet another set of new milestones in the Dow and S&P 500, as Santa Claus continues to bestow gifts on Wall Street.

DOCKET A L A R M



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.